Market Access News | pharmaphorum

News

NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months.

News

The FDA has approved Johnson & Johnson's Rybrevant Faspro for head and neck cancer, extending the franchise beyond lung cancer for the first time.

News

Bayer's oral HER2 inhibitor Hyrnuo has been approved in China as a frontline therapy for advanced, HER2-mutant non-small cell lung cancer.

News

Patients with muscle-invasive bladder cancer can now receive NHS treatment with MSD's Keytruda and Astellas' Padcev, given before and after surgery.

News

As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.

News

EVERSANA has acquired UK AI-powered health economics and outcomes research (HEOR) firm Estima to help its customers "modernise commercialisation."